Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Early Pipeline Case Study

Daiichi Sankyo logo

Daiichi gets breakthrough status for pre-NDA leukaemia drug

Quizartinib could have an advantage over rival drug Rydapt

- PMLiVE

Trust me, I’m from pharma

Chris Ross, with the help of five industry thought leaders, explores how the industry can enhance its public reputation by focusing on making a difference – rather than just making...

- PMLiVE

EMA cuts back as Brexit staff losses top expectations

Regulator says it faces loss of 30% of staff

- PMLiVE

Daily Brief: European approvals for BMS’ Opdivo, Aegerion’s lipodystrophy treatment, Pfizer’s biosimilar and Xeljanz

Will Pfizer spark price war with its Herceptin biosimilar?

- PMLiVE

Immunology keeps Shire figures solid as Takeda takeover nears

Shire’s sales increased by 6% to $3.81bn

- PMLiVE

Pfizer CEO reckons rebates will disappear, and that’s a positive

The move also has the support of FDA Commissioner Scott Gottlieb

- PMLiVE

Sanofi latest to reveal Brexit stockpiling of drugs

Company says UK job losses inevitable in event of hard or no deal Brexit

- PMLiVE

Ipsos to buy GfK Research divisions

Customer experience, experience innovation, health and public affairs all acquired

How behavioural design is transforming the role and impact of life sciences in healthcare

Behavioural economics will become essential to the future success of life sciences companies

- PMLiVE

Bringing the NHS into the 21st century

As the NHS celebrates its 70th birthday and a £20bn “birthday gift” from the UK government, we find out how one company is delivering what the National Health Service really...

Blue Latitude Health

- PMLiVE

First migraine prevention drug to hit European market

European Commission green lights Novartis’ Aimovig

- PMLiVE

Bluebird Bio: on the cusp of a gene therapy revolution

Nick Leschly talks to PME about Bluebird's remarkable gene therapy pipeline and why it’s filing first in Europe.

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links